Introduction
Androgen deprivation is a major therapeutic option for the treatment of advanced/metastatic prostate cancer, however, most responders eventually develop resistance to this therapy. Secondline systemic treatments, including new types of androgen receptor signaling inhibitors, glucocorticoids, and cytotoxic agents, have been shown to have a survival benefit in patients with castrationresistant prostate cancer (CRPC); however, the efficacy of these drugs is often short-lived [1] [2] [3] . Thus, new therapeutic targets and clinical markers are urgently required.
The atypical protein kinase C / (aPKC/) is involved in several signal transduction pathways and the establishment of epithelial cell polarity [4] . Previous studies have suggested that the deregulation of aPKC/ is associated with the pathogenesis and progression of various types of neoplasms [5] [6] [7] . Recently, the overexpression of aPKC/ and its gene amplification have been found in lung and ovarian cancers [4, [8] [9] [10] . In addition, a higher aPKC/ expression has been shown to correlate with poorer outcomes in patients with metastatic prostate cancer [11] . The present study performed immunohistochemical analyses of aPKC/ in initially metastatic prostate cancer to reveal the impact of aPKC/ expression on the prognosis in initially advanced prostate cancer.
Case presentation
A total of 43 patients with prostate cancer and associated metastasis to the lymph node and/or bone were analyzed in this study. This study was approved by the Yokohama City University Hospital Institutional Review Board and written informed consent was obtained from all enrolled patients. We performed immunohistochemistry in prostate biopsy specimens using a primary antibody raised against aPKC (dilution 1:50, BD Biosciences, San Jose, CA, USA), as previously described [12] . The Kaplan-Meier product limit estimator was used to estimate the cancer-specific survival (CSS). The survival duration was defined as the time between the pathological diagnosis and death. The results were compared using a log-rank test. P values of <0.05 were considered to indicate statistical significance. We adhered to the PROCESS criteria for this study [13, 14] .
Positive signals for aPKC were detected in both the nuclei and cytoplasm of epithelial/carcinoma cells. Because of higher expression of aPKC/, we evaluated the nuclear expression in our analysis. Overall, aPKC/was positive in 32 (74.4%) of 43 prostate cancer specimens. the aPKC/ expression and CSS or in the clinicopathological features, including the Gleason score, pT stage, and the metastatic site.
[ Fig. 2 ] We previously reported that aPKC/ was highly expressed in CRPCs in comparison to tumors that had no undergone androgen deprivation therapy [15] , but the current staining did not reveal a significant correlation between the aPKC/ expression and CSS.
Discussion
This study is a first study to investigate the aPKC/ expression in metastatic hormone sensitive prostate cancer. The current study is associated with a limitation regarding its small sample size. As a result, we could not definitively confirm the lack of any association between aPKC/ expression in the initial biopsy specimens and the prognosis. aPKC/ might contribute to tumor progression, such as the transition to CRPC rather than the aggressiveness of hormone-naive cancer. In summary, this is the first study to assess the aPKC/ expression in primary prostate cancer with metastatic disease. We found no strong association between the aPKC/ expression and the prognosis of these patients.
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